Treatment of tumors using specific anti-L1 antibody
AssigneesDeutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts, MediGene AG
InventorsDaniela Kelm, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Bärreiter, Sandra Lüttgau, Ulrich Möbius, Yi Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
Claims15
A purified anti-L1CAM monoclonal antibody which is capable of binding to the same L1CAM epitope recognized by the monoclonal antibody 9.3, produced by the hybridoma cell deposited under DSMZ ACC2841.
A purified anti-L1CAM monoclonal antibody, wherein its six complementarity determining regions (CDRs) comprise the following sequences:
- RASQDISNYLN (SEQ ID NO:
- 1), YTSRLHS (SEQ ID NO:
- 2), QQGNTLPWT (SEQ ID NO:
- 3), RYWML (SEQ ID NO:
- 4), EINPRNDRTNYNEKFKT (SEQ ID NO:
- 5), and GGGYAMDY (SEQ ID NO:
- 6).
A purified monoclonal antibody, produced by the hybridoma cell deposited under DSMZ ACC2841.
A purified antibody or antigen-binding fragment thereof comprising the following sequences:
- RASQDISNYLN (SEQ ID NO:
- 1), YTSRLHS (SEQ ID NO:
- 2), QQGNTLPWT (SEQ ID NO:
- 3), RYWML (SEQ ID NO:
- 4), EINPRNDRTNYNEKFKT (SEQ ID NO:
- 5), and GGGYAMDY (SEQ ID NO:
- 6).
The hybridoma cell deposited under DSMZ ACC2841.
Dependencies are inferred from the claim text.